Brought to you by 
Janssen teams with Second Genome to create GI therapeutics
12 Jun 2013
Executive Summary
In its first microbiome pharma deal, Second Genome Inc. has agreed to use its modulation discovery technology to characterize the role of bacteria in ulcerative colitis (UC) and help discover therapeutics for Johnson & Johnson’s Janssen Biotech Inc.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen teams with Second Genome to create GI therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice